based in silicon valley, procept biorobotics is a privately held surgical robotics company enabling better patient care by developing transformative solutions in urology. with an initial focus on benign prostatic hyperplasia (bph), the company’s first product, the aquabeam system delivering aquablation therapy, is the world’s first commercially available minimally invasive surgical robot providing autonomous tissue removal to safely and effectively treat bph. aquablation therapy offers predictable and reproducible outcomes, independent of prostate anatomy or surgeon experience.
Company profile
Ticker
PRCT
Exchange
Website
CEO
Reza Zadno
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
OF PROCEPT BIOROBOTICS CORPORATION • PROCEPT BioRobotics GmbH • PROCEPT BioRobotics UK Ltd. • PROCEPT BioRobotics K.K. ...
IRS number
260199180
PRCT stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Results of Operations and Financial Condition
27 Feb 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
PROCEPT BioRobotics® Reports Third Quarter 2023 Financial Results and Increases 2023 Revenue Guidance
1 Nov 23
8-K
Other Events
12 Sep 23
8-K
Other Events
4 Aug 23
424B5
Prospectus supplement for primary offering
3 Aug 23
424B5
Prospectus supplement for primary offering
1 Aug 23
S-3ASR
Automatic shelf registration
1 Aug 23
Transcripts
PRCT
Earnings call transcript
2023 Q4
27 Feb 24
PRCT
Earnings call transcript
2023 Q3
1 Nov 23
PRCT
Earnings call transcript
2023 Q2
27 Jul 23
PRCT
Earnings call transcript
2023 Q1
30 Apr 23
PRCT
Earnings call transcript
2023 Q1
27 Apr 23
PRCT
Earnings call transcript
2022 Q4
28 Feb 23
PRCT
Earnings call transcript
2022 Q3
6 Nov 22
PRCT
Earnings call transcript
2022 Q2
7 Aug 22
PRCT
Earnings call transcript
2022 Q1
8 May 22
PRCT
Earnings call transcript
2021 Q4
8 Mar 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 290.90 mm | 290.90 mm | 290.90 mm | 290.90 mm | 290.90 mm | 290.90 mm |
Cash burn (monthly) | (no burn) | (no burn) | 8.54 mm | 8.72 mm | 6.31 mm | 9.03 mm |
Cash used (since last report) | n/a | n/a | 50.85 mm | 51.95 mm | 37.61 mm | 53.80 mm |
Cash remaining | n/a | n/a | 240.05 mm | 238.95 mm | 253.29 mm | 237.10 mm |
Runway (months of cash) | n/a | n/a | 28.1 | 27.4 | 40.1 | 26.3 |
Institutional ownership, Q3 2023
87.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 125 |
Opened positions | 19 |
Closed positions | 17 |
Increased positions | 62 |
Reduced positions | 27 |
13F shares | Current |
---|---|
Total value | 1.41 tn |
Total shares | 44.39 mm |
Total puts | 86.70 k |
Total calls | 281.40 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
FMR | 7.55 mm | $247.83 bn |
CPMG | 5.33 mm | $174.84 bn |
Vanguard | 4.07 mm | $133.70 bn |
T. Rowe Price Investment Management | 3.65 mm | $119.92 bn |
BLK Blackrock | 2.94 mm | $96.59 bn |
T. Rowe Price | 1.76 mm | $57.71 bn |
Champlain Investment Partners | 1.57 mm | $51.46 bn |
Loomis Sayles & Co L P | 1.35 mm | $44.14 mm |
Citadel Advisors | 1.11 mm | $36.56 bn |
STT State Street | 1.03 mm | $33.85 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Mar 24 | Hisham Shiblaq | Common Stock | Sell | Dispose S | No | No | 48.83 | 244 | 11.91 k | 55,860 |
18 Mar 24 | Reza Zadno | Common Stock | Sell | Dispose S | No | No | 48.83 | 5,391 | 263.24 k | 241,319 |
18 Mar 24 | Kevin Waters | Common Stock | Sell | Dispose S | No | No | 48.83 | 1,024 | 50.00 k | 102,149 |
18 Mar 24 | Alaleh Nouri | Common Stock | Sell | Dispose S | No | No | 48.83 | 441 | 21.53 k | 62,472 |
15 Mar 24 | Kevin Waters | Common Stock | Option exercise | Acquire M | No | No | 4.56 | 17,747 | 80.93 k | 103,173 |
15 Mar 24 | Kevin Waters | Common Stock | Option exercise | Acquire M | No | No | 4.52 | 36,010 | 162.77 k | 85,426 |
15 Mar 24 | Kevin Waters | Stock Option Common Stock | Option exercise | Dispose M | No | No | 4.56 | 17,747 | 80.93 k | 53,243 |
15 Mar 24 | Kevin Waters | Stock Option Common Stock | Option exercise | Dispose M | No | No | 4.52 | 36,010 | 162.77 k | 15,917 |
News
Truist Securities Maintains Buy Rating for PROCEPT BioRobotics: Here's What You Need To Know
28 Feb 24
Truist Securities Maintains Buy on PROCEPT BioRobotics, Raises Price Target to $58
28 Feb 24
PROCEPT BioRobotics Projects Full Year 2024 Revenue To Be Approximately $210M, Est $204.458M
27 Feb 24
PROCEPT BioRobotics: Q4 Earnings Insights
27 Feb 24
PROCEPT BioRobotics Q4 2023 GAAP EPS $(0.54) Misses $(0.44) Estimate, Sales $43.58M Beat $42.06M Estimate
27 Feb 24